What is Behavidence?
Founded in 2020 by a team of experts in neuroscience, neuropsychology, medicine, and bioengineering, Behavidence develops advanced digital phenotyping solutions. These tools leverage passive digital biomarkers to detect and assist in the remote monitoring and management of mental health conditions. The company's technology offers predictive models for disorders such as depression, anxiety, and ADHD, and has been adopted by various health organizations, tech companies, and government entities. Behavidence's products serve as measurement-based outcomes for monitoring employee burnout, stress, predicting condition relapse, screening, and facilitating remote monitoring for clinical interventions. The solution prioritizes user privacy and offers real-time feedback with zero respondent burden.
How much funding has Behavidence raised?
Behavidence has raised a total of $4.3M across 1 funding round:
Angel/Seed
$4.3M
Angel/Seed (2022): $4.3M with participation from Arc Impact, Welltech Ventures, and Longevity Venture Partners
Key Investors in Behavidence
Arc Impact
Arc Impact is an investor focused on early-stage companies in sectors including healthcare and assistive technologies, with a mission to enhance accessibility and improve health outcomes.
Welltech Ventures
Welltech Ventures is a venture capital fund dedicated to wellness technology, investing in startups that leverage innovation in areas like mental health to help people live healthier lives.
Longevity Venture Partners
Longevity Venture Partners is an early-stage venture capital firm that supports entrepreneurs in the Silvertech, Healthcare, and Wellness sectors, aiming to accelerate global growth for its portfolio companies.
What's next for Behavidence?
With its recent major strategic investment and substantial total funding, Behavidence is poised for significant expansion. The company's focus on improving mental health through innovative technology aligns with a growing market demand for accessible and data-driven healthcare solutions. Future growth is likely to involve scaling its adoption across healthcare providers, corporate wellness programs, and potentially government agencies. Continued development of its digital phenotyping models and the integration of new biomarkers will be crucial for maintaining its competitive edge in the rapidly evolving digital health landscape. This enterprise-level backing suggests a strategic push towards broader market penetration and further technological advancement.
See full Behavidence company page
